AI in Oncology Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global AI in Oncology Market- (Type of Cancer (Solid malignancies, Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Brain tumor, Others), By End User (Hospitals, Pharmaceutical companies, Research Institutes, Others)), By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031.”
According to the latest research by InsightAce Analytic, the Global AI in Oncology Market is valued at US$ 1.2 Bn in 2023, and it is expected to reach US$ 4.5 Bn by 2031, with a CAGR of 18.8% during the forecast period of 2024-2031.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2529
Artificial intelligence (AI) is revolutionizing the oncology sector by enhancing cancer diagnostics, treatment planning, and patient management through sophisticated machine learning algorithms and advanced data analytics. By analyzing large and complex medical datasets, AI systems can detect subtle patterns and provide personalized therapeutic recommendations, thereby supporting informed clinical decision-making and improving patient outcomes. Core technologies, including deep learning, natural language processing (NLP), computer vision, and genomics-based analytics, are instrumental in enhancing diagnostic precision, optimizing treatment strategies, and increasing overall healthcare efficiency.
The strategic value of AI in oncology lies in its capacity to deliver precise, data-driven insights that enable accurate diagnoses and individualized care tailored to each patient’s clinical profile. AI-enabled platforms also facilitate early disease detection by evaluating patient data to identify potential health risks, promoting proactive and preventive interventions. In addition, AI-driven automation contributes to operational efficiency, reduces healthcare costs, and streamlines clinical workflows, establishing artificial intelligence as a transformative force within oncology and the broader healthcare ecosystem.
List of Prominent Players in the AI in Oncology Market:
• Berg
• CancerCenter.AI
• Concert AI
• GE Healthcare
• IBM Watson Health
• iCAD
• JLK Inspection
• Median Technologies
• Path AI
• Roche Diagnostics
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02
Market Dynamics of AI in Oncology
Market Drivers:
The rising global incidence of cancer, including prevalent types such as lung, breast, prostate, colorectal, and brain cancers, is a primary factor driving the adoption of AI technologies in oncology. The American Cancer Society’s 2024 report projects approximately 234,580 new lung cancer cases and 125,070 related deaths in the United States, highlighting the critical demand for advanced oncological solutions.
On a global scale, the World Health Organization (WHO) estimates nearly 20 million new cancer diagnoses annually, further intensifying the need for enhanced diagnostic and therapeutic interventions. AI-enabled precision medicine, which integrates complex genomic datasets, advanced medical imaging, and sophisticated analytics, plays a pivotal role in improving early cancer detection, optimizing individualized treatment plans, and elevating overall patient care outcomes.
Market Challenges:
Despite significant promise, the widespread integration of AI in oncology is hindered by several obstacles. Key challenges include the limited availability of high-quality, multi-institutional datasets and inconsistencies in electronic health record (EHR) data capture, which impede interoperability. The absence of standardized imaging protocols and unified data-sharing frameworks further constrains clinical implementation, potentially affecting diagnostic accuracy and treatment efficacy.
Additionally, labor-intensive processes such as tumor segmentation and annotation reduce the scalability of AI solutions. Successful deployment also relies on effective collaboration among oncologists, radiologists, and data scientists, which can present operational complexities in multidisciplinary healthcare environments.
Regional Trends:
North America currently leads the AI oncology market, underpinned by a sophisticated healthcare infrastructure, advanced medical imaging capabilities, and a robust research ecosystem. In 2024, the U.S. is projected to record approximately 2,001,140 new cancer cases and 611,720 cancer-related deaths, underscoring the urgent need for innovative cancer care technologies.
The region benefits from substantial investments in research and development by leading academic institutions and biotechnology firms, driving the advancement of AI-powered oncology applications. Furthermore, a supportive regulatory framework, including favorable reimbursement policies, facilitates the rapid clinical adoption of AI solutions. Rising demand for precise, efficient diagnostic and therapeutic tools continues to reinforce North America’s leadership in AI-driven oncology innovation.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2529
Recent Developments:
• In May 2024, ConcertAI launched CARA AI, its advanced predictive and generative AI suite, at the 2024 ASCO Annual Meeting, offering multi-modal data management and fostering collaborative research efforts across translational to clinical development stages. Additionally, ConcertAI introduced an update to its SmartLinQ oncology quality management platform, TriaLinQ.
• In May 2024, GE Healthcare introduces Revolution RT, its new AI-enhanced oncology solution, marking a “new era” in radiation therapy computed tomography (CT). Revolution RT features innovative hardware and software to enhance imaging accuracy and streamline simulation workflows, aiming to personalize and simplify the oncology care pathway for clinicians and patients. The technology debuted at the European Society for Therapeutic Radiology and Oncology 2024 Congress in Glasgow, Scotland.
Segmentation of AI in Oncology Market-
By Type of Cancer
• Solid malignancies
• Breast cancer
• Lung cancer
• Prostate cancer
• Colorectal cancer
• Brain tumor
• Others
By End User
• Hospitals
• Pharmaceutical companies
• Research Institutes
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa
Read Overview Report- https://www.insightaceanalytic.com/report/ai-in-oncology-market-/2529
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com
This release was published on openPR.
